Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Yoshihide, Fukuda"'
Autor:
M. Imoto, Masahiko Yamada, J. Takamatsu, Yoshihide Fukuda, Tetsuo Hayakawa, Isao Nakano, Yasuo Koyama, Ken-ichi Isobe, Fumihiro Urano
Publikováno v:
European Journal of Haematology. 57:165-170
Twenty-one HIV negative Japanese patients with chronic hepatitis C who had congenital bleeding disorders, 15 hemophilia A, 3 hemophilia B, 1 von Willebrand's disease, 1 afibrinogenemia and 1 thrombasthenia, were treated with 9 million units 3 times a
Autor:
Noboru Fujimoto, Isao Nakano, Tetsuo Hayakawa, Mieko Ebata, Yoshiaki Katano, Yoshihide Fukuda
Publikováno v:
Liver. 17:293-299
Serum levels of tissue inhibitor of metalloproteinases-2 (TIMP2) and of precursor form of matrix metalloproteinase-2 (proMMP2) were determined in patients with chronic hepatitis and hepatocellular carcinoma by a one-step sandwich enzyme immunoassay.
Autor:
Kazuo Isobe, Isao Nakano, Yasuo Koyama, Yoshihide Fukuda, Junki Takamatsu, Masami Imoto, Tetsuo Hayakawa
Publikováno v:
Liver. 15:131-134
Liver function and antibodies to hepatitis C virus and to human immunodeficiency virus-1 were examined in 195 Japanese patients with hemophilia. One hundred and seventy-three were positive for antibody to HCV and 61 for antibody to human immunodefici
Autor:
Hidemi Goto, Yuzo Sato, Taro Murakami, Isao Nakano, Masaru Nagasaki, Takashi Honda, Yoshiaki Katano, Yoshihide Fukuda, Yoshiharu Shimomura
Publikováno v:
Journal of Hepatology. 40:439-445
Background/Aims : Branched-chain α-keto acid dehydrogenase (BCKDH) complex catalyses the committed step in the branched-chain amino acid (BCAA) catabolic pathway. In many cases of liver failure, the serum BCAAs/aromatic amino acids ratio (Fisher's r
Autor:
Yoshihide Fukuda, Isao Nakano, Kazuhiko Hayashi, Takashi Kumada, Satoshi Nakano, Yoshiaki Katano, Hidenori Toyoda
Publikováno v:
Journal of Medical Virology. 74:54-61
Hepatitis C virus (HCV) genotype 1b comprises mainly two subtypes in Japan, each named for its geographic prevalence (Japan-specific, J type; worldwide, W type). Because the newly identified subtypes have not been fully characterized, the present stu
Autor:
Yoshihide Fukuda, Junki Takamatsu, Isao Nakano, Kazuhiko Hayashi, Hidenori Toyoda, Patrick Goubau, Ching-Wen Teng, Hsin-Fu Liu
Publikováno v:
Journal of Medical Virology. 71:385-390
GB virus C (GBV-C) or hepatitis G virus (HGV) has been transmitted to Japanese patients with hemophilia through the frequent use of unheated blood products. Sequence analysis showed that most of the viruses isolated from these patients belonged to GB
Autor:
Isao Nakano, Yoshihide Fukuda, Yoshiaki Katano, Tetsurou Nagasaka, Kenichi Nagano, Tetsuo Hayakawa, Toshiaki Nonami, Hidenori Toyoda
Publikováno v:
Journal of Gastroenterology and Hepatology. 14:163-167
Background: Reactive lymphoid hyperplasia of the liver is an extremely rare entity, with six cases reported so far. Methods: We encountered a 47-year-old Japanese female with reactive lymphoid hyperplasia of the liver, which coexisted with chronic th
Autor:
Isao Nakano, Honda T, Yasuhiro Sone, T Hayakawa, Seiki Kiriyama, Takashi Kumada, Yoshihide Fukuda, H Shimizu, Satoshi Nakano, K Watanabe
Publikováno v:
Gut. 50:266-270
Background: 5-Nitro-o-toluidine is an aromatic nitro amino compound. While other aromatic compounds are known to damage the human liver and are registered as toxic substances, toxicity information concerning 5-nitro-o-toluidine is lacking. Aims: To i
Autor:
Yoshiaki Katano, Tetsuo Hayakawa, Hidenori Toyoda, Yoshihide Fukuda, Junki Takamatsu, Moritoshi Kinoshita, Shouichi Yokozaki, Youji Fukuda, Isao Nakano, Kazuhiko Hayashi
Publikováno v:
Kanzo. 43:11-17
血友病患者のC型慢性肝炎 (CHC) 43例のC型肝炎ウイルス (HCV) 遺伝子型を, HCVモニターゲノタイプ法とHCV core 領域での判定法を用いて測定した. 1a型が13例, 1b型が11例, 2a型が4例, 2b型が1例, 3a型
Autor:
J. Takamatsu, Hidenori Toyoda, Yoshihide Fukuda, Shouichi Yokozaki, Kazuhiko Hayashi, Isao Nakano, Hidehiko Saito
Publikováno v:
Haemophilia. 7:575-581
In multiply coinfected human immunodeficiency virus (HIV)-positive patients, we investigated the effects of high-activity antiretroviral therapy (HAART) using HIV protease inhibitors on three other viruses: hepatitis C virus (HCV), hepatitis G virus